Trending...
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
- Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
DURHAM, N.C.--(BUSINESS WIRE)--Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries based in Durham, North Carolina, today announced the acquisition of NoviSci, Inc., a software analytics and services company whose innovative technologies enable the visualization and analysis of health data using modern epidemiological methods and sound scientific principles. The acquisition significantly broadens Target RWE's data analytics capabilities and will enable the company to meet increasing demand for high quality evidence from real-world data.
Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital. This expanded partnership further validates the importance of real-world data on a global scale and the differentiated capabilities and solutions that Target RWE and NoviSci offer together. Financial terms of the transactions were not disclosed.
Neal Bibeau, Chief Executive Officer of Target RWE, said, "Target RWE's proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. With the addition of NoviSci's novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations."
More on ncarol.com
"Now more than ever, real-world evidence solutions are transforming healthcare. Our expanding longitudinal, observational data augmented with new sources of data allow for deep characterization of patient journeys across a broad range of diseases and treatments," added Michael W. Fried, MD, FAASLD, Chief Medical Officer and Co-founder of Target RWE. "NoviSci's expertise and novel analytical software complements our leading real-world evidence platform, and we look forward to integrating these products to enable accelerated growth in our industry."
Durham-based NoviSci, Inc. applies epidemiologic methods and causal inference techniques from the fields of epidemiology and statistics to complex real-world data to support its partners in research and industry. NoviSci has built a novel repository of rigorously developed interactive real-world studies that can be adapted to new datasets and populations. All study results are rendered in NoviSci's secure web-based environment, featuring interactive content and compelling data visualizations that can be updated with accumulating data. NoviSci's tools also support all critical aspects of scientific knowledge production, peer review, and sharing.
M. Alan Brookhart Ph.D., Co-Founder and Chief Scientist of NoviSci and Professor of Population Health Sciences at Duke University, said, "We are delighted to have the opportunity to apply our analytic technology to Target RWE's unique data assets and to provide timely, relevant, and useful answers to important questions posed by stakeholders across the healthcare ecosystem."
Aaron McKethan, Co-Founder and CEO of NoviSci added, "Our goal is to make it easier and faster to answer important questions in health care that result in better outcomes for people and populations. We have sought to use technology to bring the craft of scientific expertise to greater scale, particularly as research methods and data sources have become more complex."
More on ncarol.com
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe, and other non-U.S. locations. Target RWE's data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Target RWE is backed by Norwest Venture Partners, 22C Capital and other strategic investors.
Visit www.targetrwe.com for more details.
About NoviSci Inc.
Headquartered in Durham, NC, NoviSci's mission is to use principled data science to improve population health outcomes for vulnerable patients with complex conditions. The company's novel analytic applications facilitate the efficient deployment of complex research methods from epidemiology and statistics as well as intuitive, interactive visualization of complex results from real-world studies. NoviSci's founders and leaders continue to hold faculty appointments, including at the Duke University School of Medicine and the University of North Carolina at Chapel Hill. NoviSci previously received seed investment from Amgen Ventures and Hatteras Venture Partners and is based in the American Underground campus in downtown Durham, NC.
Visit www.novisci.com for more details.
Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital. This expanded partnership further validates the importance of real-world data on a global scale and the differentiated capabilities and solutions that Target RWE and NoviSci offer together. Financial terms of the transactions were not disclosed.
Neal Bibeau, Chief Executive Officer of Target RWE, said, "Target RWE's proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. With the addition of NoviSci's novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations."
More on ncarol.com
- TransmetriQ Introduces VIN-Level Rail Tracking to Improve Visibility of Finished Vehicle Shipments
- The OpenSSL Corporation Releases Its Annual Report 2025
- Iranian-Born Engineer Mohsen Bahmani Introduces Propeller-Less Propulsion for Urban Air Mobility
- Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
- RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
"Now more than ever, real-world evidence solutions are transforming healthcare. Our expanding longitudinal, observational data augmented with new sources of data allow for deep characterization of patient journeys across a broad range of diseases and treatments," added Michael W. Fried, MD, FAASLD, Chief Medical Officer and Co-founder of Target RWE. "NoviSci's expertise and novel analytical software complements our leading real-world evidence platform, and we look forward to integrating these products to enable accelerated growth in our industry."
Durham-based NoviSci, Inc. applies epidemiologic methods and causal inference techniques from the fields of epidemiology and statistics to complex real-world data to support its partners in research and industry. NoviSci has built a novel repository of rigorously developed interactive real-world studies that can be adapted to new datasets and populations. All study results are rendered in NoviSci's secure web-based environment, featuring interactive content and compelling data visualizations that can be updated with accumulating data. NoviSci's tools also support all critical aspects of scientific knowledge production, peer review, and sharing.
M. Alan Brookhart Ph.D., Co-Founder and Chief Scientist of NoviSci and Professor of Population Health Sciences at Duke University, said, "We are delighted to have the opportunity to apply our analytic technology to Target RWE's unique data assets and to provide timely, relevant, and useful answers to important questions posed by stakeholders across the healthcare ecosystem."
Aaron McKethan, Co-Founder and CEO of NoviSci added, "Our goal is to make it easier and faster to answer important questions in health care that result in better outcomes for people and populations. We have sought to use technology to bring the craft of scientific expertise to greater scale, particularly as research methods and data sources have become more complex."
More on ncarol.com
- Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
- 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
- OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
- New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
- Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe, and other non-U.S. locations. Target RWE's data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Target RWE is backed by Norwest Venture Partners, 22C Capital and other strategic investors.
Visit www.targetrwe.com for more details.
About NoviSci Inc.
Headquartered in Durham, NC, NoviSci's mission is to use principled data science to improve population health outcomes for vulnerable patients with complex conditions. The company's novel analytic applications facilitate the efficient deployment of complex research methods from epidemiology and statistics as well as intuitive, interactive visualization of complex results from real-world studies. NoviSci's founders and leaders continue to hold faculty appointments, including at the Duke University School of Medicine and the University of North Carolina at Chapel Hill. NoviSci previously received seed investment from Amgen Ventures and Hatteras Venture Partners and is based in the American Underground campus in downtown Durham, NC.
Visit www.novisci.com for more details.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Mend Colorado Launches Revamped Sports Performance Training Page
- Rotary Club of Charlotte South Hosts 4th Annual "Perfectly Paired" Wine Tasting & Auction
- Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
- Costa Oil Named Primary Sponsor of Carson Ware for the United Rentals 300 at Daytona International Speedway
- From Gen Z to Gen Alpha: The One Ingredient That Matters More Than Ever in STEM
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto
- Elixia Rebrands as Empathx Research Marking a New Era in Patient-Centered Recruitment
- Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026
- RTC Communications Completes Next Level Connect Fiber Expansion Bringing Multi-Gig Broadband to West Boggs Community
- EPP Pricing Platform announces leadership transition to support long-term growth and continuity
- Stolen Hearts: Reclaiming Your Child From Parental Alienation (narcissistic abuse)
- Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
- Regional Real Estate Powerhouse
- A Valentine's Experience at Project 1610